

# Molecular study of *Shigella dysenteriae* Aminoglycoside Resistance Genes Isolated from Children and its Expression Under the Influence of Curcumin Nanoparticle

Neginsadat Mireshghi<sup>1</sup>, Zohreh Jafari<sup>1</sup>, Behrooz Shojaei Sadi<sup>1</sup>

1. Department of Microbiology, Science Faculty, Arak Branch, Islamic Azad University, Arak, Iran

## ABSTRACT

**Background and Aim:** *Shigella* is the causative agent of shigellosis in the world. Antibiotic treatment is important in this bacterium, but recently *Shigella* species containing the *aph*, *aadE*, *aacA-aphD* genes have shown resistance to aminoglycosides and have hampered the treatment process. Therefore, the aim of this study is a molecular investigation of *Shigella dysenteriae* aminoglycoside resistance genes isolated from children and its expression under the influence of curcumin nanoparticles.

**Materials and Methods:** In this study, 60 diarrhea samples collected from Tehran hospitals in 2022 were used. *Shigella dysenteriae* isolates were identified by biochemical and microbial tests.

The presence of *aadE*, *aacA-aphD*, and *aph* genes was confirmed by the Multiplex-PCR method. Then, real-time PCR was used to investigate the expression of *aadE* gene in the presence of curcumin nanoparticles.

**Results:** From the 60 diarrhea samples examined, 12 strains (40%) of *Shigella dysenteriae* were identified by biochemical tests. Ten isolates (83.3%) carried the *aadE* gene, six isolates carried the *aacA-aphD* gene, and one isolate carried the *aph* gene. The Sub MIC value of curcumin nanoparticles on *aadE* gene expression is 128 µg/mL, and the Fold Change for this gene is -1.03.

**Conclusion:** Considering the presence of *aadE* gene in 83.3% of *S. dysenteriae* isolates, it is important to investigate the presence of this gene in providing a suitable treatment model for patients infected with this bacterium, as well as the expression of *aadE* gene as the most common one. The expression of the aminoglycoside resistance gene was reduced to a relative amount in the presence of curcumin nanoparticles. Therefore, curcumin nanoparticles can be a suitable alternative for the treatment of strains carrying aminoglycoside resistance genes.

**Keywords:** *Shigella dysenteriae*, Drug Resistance, Aminoglycoside, Curcumin, Nanoparticles

Received: 2022/06/07;

Accepted: 2022/08/12;

Published Online: 2023/01/20

## Corresponding Information:

Zohreh Jafari, Department of Microbiology, Science Faculty, Arak Branch, Islamic Azad University, Arak, Iran  
Email: [jafarizohreh264@gmail.com](mailto:jafarizohreh264@gmail.com)



Copyright © 2023, This is an original open-access article distributed under the terms of the Creative Commons Attribution-noncommercial 4.0 International License which permits copy and redistribution of the material just in noncommercial usage with proper citation.



Use a device to scan  
and read the article online

Mireshghi N, Jafari Z, Shojaei Sadi B. Molecular study of *Shigella dysenteriae* Aminoglycoside Resistance Genes Isolated from Children and its Expression Under the Influence of Curcumin Nanoparticle. Iran J Med Microbiol. 2023; 17(1):50-7.

**Download citation:** [BibTeX](#) | [RIS](#) | [EndNote](#) | [Medlars](#) | [ProCite](#) | [Reference Manager](#) | [RefWorks](#)

**Send citation to:**  [Mendeley](#)  [Zotero](#)  [RefWorks](#)

## 1. Introduction

Shigellosis or basil bloody diarrhea is the second leading cause of death in children under the age of 5, especially in developed and developing countries. The cause of this disease is a bacterium called *Shigella*. *Shigella* are facultative anaerobic gram-

negative bacilli, non-motile and without spores, which have 4 subgroups: *Shigella dysenteriae*, *Shigella flexneri*, *Shigella boydii*, and *Shigella sonnei* (1, 2). Shigellosis with low infectious dose (10-100 bacteria), the emergence of antibiotic resistance,

complications, and high mortality have been major global health problems. Statistics show that *Shigella* is the cause of 165 million bloody diarrhea that occurs per year, so prevention and timely treatment of this disease is significant (3, 4). The most important way to get it into the body is fecal-oral. Due to the low-speed infectious dose, its transmission from person to person is very high so this disease can spread in communities with health poverty (5-7). The most important damage of this bacterium is its invasion of mucosal epithelial cells (M cells) which causes damage to the coating tissue and ulcers in the intestinal mucosa. Finally, with the loss of blood and release of inflammatory elements and mucus, water absorption is prevented, the volume of feces changes and bloody and mucous diarrhea occurs (8, 9). The rate of increase of antimicrobial resistance in *Shigella* isolated from humans has become important during the last two decades.

Recent studies show that *Shigella* can acquire antibiotic-resistance genes, including aminoglycosides, through plasmids and integrons (10). Aminoglycosides are a group of antibiotics that bind to the 30s component of bacterial ribosomes to inhibit the synthesis of bacterial proteins. Ultimately, it reduces or eliminates the power of pathogenicity. The clinical significance of these antibiotics is that they positively affect a wide range of facultative anaerobic bacteria such as gram-negative, *staphylococci*, and *streptococci*, and are used in bacilli infections such as *Shigella*. *Shigella* contain aminoglycoside-modifying enzymes (AMEs), and these enzymes cause resistance through three reactions: Adenylation, Phosphorylation, and Acetylation. Recent studies have shown that *aadA1* and *aadA2* genes are present in *Enterobacteriaceae*, especially *Shigella*, which cause resistance to streptomycin and spectinomycin (11, 12). There are strains of *Campylobacter jejuni* that have the *aph3-1* and *aadE* genes that make them resistant to aminoglycosides. The *aadE* gene induces resistance to streptomycin (13).

Also, the *aph* gene has been shown to cause resistance to neomycin and kanamycin in gram-negative gut bacteria. The *aac* gene is one of the most important aminoglycoside resistance genes that cause gentamicin resistance in gram-negative bacteria such as *Shigella*. Unfortunately, gentamicin resistance is widespread in these strains today (14). Curcumin is a polyphenolic compound with the chemical name Diferuloylmethane and the chemical formula C<sub>21</sub>H<sub>20</sub>O<sub>6</sub>, extracted from turmeric and widely used in the food industry. Turmeric root contains 2-9 % of curcumin. For centuries, Asian countries have used turmeric as an antibacterial, anti-inflammatory and anti-cancer agent in their

traditional medicine. Curcumin exerts its therapeutic effects by interacting with biological molecules such as tumor cytokines, transcription factors, kinases, enzymes, receptors, growth factors, and proteins (15, 16). The possible mechanisms of action of curcumin that scientists have found are that initially, by forming an ion channel, it causes pores in the outer membrane and the cell wall. With the outflow of important metabolites of the bacterial cell, it eventually leads to the death of the bacterium. In addition, the bacteriostatic function of curcumin by inhibiting the bacteria's DNA repair process is also considered an antibacterial mechanism of curcumin (17, 18). Curcumin has been reported to inhibit the growth of various *Shigella* species in appropriate doses (19). Therefore, the aim of this study is to investigate the molecular resistance genes to the aminoglycoside of *S. dysenteriae* isolated from children and the expression of *aadE* under the influence of curcumin nanoparticles.

## 2. Materials and Methods

### Sampling and Isolation

In this cross-sectional study, 60 stool samples were collected randomly from children less than ten years old with diarrhea referred to Tehran hospitals, Iran, in 2022. All samples were transferred to Pasargad Laboratory (Tehran, Iran). The samples were first cultured on MacConkey agar and then Salmonella-Shigella agar (Merck Co. Germany) and incubated at 37°C for 24h. After identifying and confirming the presence of *Shigella* bacteria, differential tests of TSI (Triple sugar iron agar) (Merck Co., Germany), IMViC, urease and decarboxylation of amino acids ornithine, and mannitol were conducted for the final diagnosis of *S. dysenteriae* species (1, 19).

### Antibiogram Test

Antibiotic sensitivity test using the disk diffusion method and based on the instructions of the Laboratory and Clinical Standards Institute (1977), on Mueller Hinton Agar medium (Merck, Germany) was conducted for gentamicin (10µg), kanamycin (30µg), vancomycin (30µg), Tobramycin (30µg), amikacin (30µg) antibiotics (manufactured by Himedia, India).

### DNA Extraction and Multiplex PCR Reaction

After bacterial DNA extraction using DNA Cinnagen kit and confirmation of the extracted DNA purity using a biophotometer (Bio-Rad, USA), The *aadE*, *aacA-aphD*, and *aph* genes were amplified BY using Multiplex PCR method and specific primer sequences (Table 1) in a thermocycler (Eppendorf, Germany) in the final volume of 20 µL including 10 µL PCR master mix 2X (Sinaclon, Iran) containing Taq DNA

polymerase (0.05 U/ $\mu$ L), MgCl<sub>2</sub>(3mM) and dNTPs (10mM), 1  $\mu$ L of each primer, 4  $\mu$ L of template DNA (40 ng) and 4  $\mu$ L of double-distilled water for 33 cycles. Thermal cycling included a denaturation step

at 95°C for 30 sec, primer annealing at 30°C for 55 sec, and an elongation step at 72°C for 60 s. Finally, PCR products were run on 1% agarose gel.

**Table 1.** Primers used in Multiplex-PCR (20-22)

| GEN               | Primer sequence         | Size  |
|-------------------|-------------------------|-------|
| <i>aadE</i>       | GCCCTTGGAAGAGTTAGATAATT | 198bp |
|                   | CGGCACAATCCTTTAATAACA   |       |
| <i>aacA- aphD</i> | CCAAGAGCAATAAGGGCATA    | 220bp |
|                   | CACTATCATAACCACTACCC    |       |
| <i>aph</i>        | GAGGGCTTTAGGAATTACGC    | 125bp |
|                   | ACACACCGACCAACAGAGG     |       |

#### Preparation of *Shigella dysenteriae* Microbial Suspension with a Concentration Equivalent to 0.5 McFarland

The reason for preparing 0.5 McFarland is that in the sense of standard inoculation for microbial tests, standard barium sulfate equal to half-McFarland standard should be used. For example, a 0.5 McFarland tube contained an approximate density of bacteria. To prepare this standard, 0.05 mL of barium chloride 1% was mixed with 9.95 mL of sulfuric acid 1%. Bacterial culture is required for 24 hours to prepare the microbial suspension. Therefore, 24 hours before the experiment, the culture is inoculated with nutrient agar in a sloping medium and incubated for 24 hours at 37°C. A 24-hour bacterial culture was used and dissolved in normal saline. The suspension was returned at 530 nm with the absorption of 0.5 McFarland solution. In other words, the produced suspension should contain  $1.5 \times 10^8$  (21).

#### Preparation of Curcumin Nanoparticle Suspension

All nanoparticle formulations were measured in the range of 2–40 nm as determined by electron microscopy (23). To prepare the nanoparticle stock solution, 10 grams of nanoparticles were suspended in one liter of 50% dimethyl sulfoxide (DMSO) as an auxiliary solvent, and the Ultrasonic RK 31 H was used for 30 minutes to properly disperse them (24, 25).

#### Determination of MIC Nano Curcumin

This method used a 96-cell micro-plate with 12 rows containing 100  $\mu$ L of sterile Mueller Hinton Broth medium. Then 100  $\mu$ L of high dilution nanoparticles of 1024 $\mu$ g / mL curcumin was added to the first row containing 100  $\mu$ L of Mueller Hinton Broth, and dilution was done until 128 dilutions (128-1024  $\mu$ g / mL). Next, 100  $\mu$ L of half-McFarland microbial suspension was added to all wells. Also, two rows of wells were used as the positive control (environment and microbial suspension) and

negative control (environment + curcumin nanoparticles) of the test. Then the microplates were incubated in a shaker incubator (200 rpm, 37°C for a maximum of 24 hours) (26). Next, we will investigate the expression of *aadE* gene in the presence of curcumin nanoparticles.

#### Real-time PCR Test

RNA was extracted by Qiagen RNeasy microkit from strains carrying the *aadE* gene based on the Sub MIC and considering both treated and untreated groups in the logarithmic growth phase (at 0.4-0.6 = OD600). Also, Qiagen DNase kit was used to remove DNA. The accuracy of RNA extraction was assessed by spectrophotometry. cDNA was synthesized using Roche's Reverse AMV enzyme. The required volume for a Real-Time polymerase chain reaction is 20  $\mu$ L, and this reaction is conducted using the Genet bio CAT kit. NO: Q9210 South Korea was done as follows: 10  $\mu$ L of Primer Qmaster mix (2x) with syber green, 5  $\mu$ L of Depc water, 1  $\mu$ L of Primer Forward, 1  $\mu$ L of Primer Reverse, 1  $\mu$ L of Rox color, and 2  $\mu$ L of cDNA was used. Amplification of the desired parts was done in the Corbet machine with an initial denaturation program of 95°C for 1 minute / 95°C for 30 seconds / 59°C for 40 seconds / 72°C for 60 seconds, in 35 cycles. The 16 SrRNA home gene was used as an internal control of the test (26).

### 3. Results

#### Cultivation, Isolation, and Identity of Bacteria

A total of 60 stool samples suspected of *Shigella dysenteriae* were collected from 4 to 10-year-old children with diarrhea referred to Tehran Hospitals, in Pasargad Research Laboratory (Tehran, Iran). Colorless colonies on McConkey agar and Salmonella-Shigella agar were considered positive samples. Among the analyzed samples, 12 isolates belonged to the *Shigella dysenteriae* strain, which had the biochemical characteristics of lactose negative, gas negative, indole negative, non-motion, ornithine and mannitol decarboxylation reaction negative, urease negative, and

citrate negative, methyl red positive and Voges-Proskauer negative.

#### Sensitivity Test

8 isolates showed resistance to gentamicin and tobramycin, 1 isolate to amikacin, 1 isolate to kanamycin, and no resistance was observed against vancomycin. No resistance was observed in 2 isolates.

#### Multiplex PCR Reaction

From 12 *Shigella dysenteriae* isolates identified according to Figure 1, 10 isolates (83.3%) carried the *aadE* gene, 6 isolates carried the *aacA-aphD* gene, and 1 isolate carried the *aph* gene.


#### MIC Test

The results of the MIC of curcumin nanoparticles in *Shigella dysenteriae* showed that the minimum concentration of growth inhibition in the presence of curcumin nanoparticles was 225 µg/mL and the Sub MIC


of curcumin nanoparticles to reduce *aadE* gene expression was 128 µg/mL.

#### *aadE* Gene Expression after Exposure to Curcumin Nanoparticles

Due to the greater abundance of *aadE* gene, the expression of this gene was measured under the influence of curcumin nanoparticles, and by using the Real-time PCR technique, the reproduction curve is shown in Figure 2. The relative expression of *aadE* gene in isolates treated with Curcumin nanoparticles showed a significant change compared to the isolates untreated and based on the results, the P-value for *aadE* gene is less than 0.05, which indicates the significance of the difference in the expression of these two genes between the treated and untreated groups. The Fold Change parameter for the *aadE* gene is -1.03, indicating that this gene was reduced by 1.03 times in the treated group compared to the untreated group.



**Figure 1.** Results of Multiplex PCR and electrophoresis on some positive isolates from samples 1 to 12, 100 bp marker, +: positive control, and -: negative control.



**Figure 2.** Results of Real-Time PCR reproduction curve of *aadE* gene related to aminoglycoside resistance.

## 4. Discussion

Shigellosis or basil bloody diarrhea is important due to the prevalence of bacteria strains resistant to aminoglycosides and high mortality in children under 5, so early diagnosis and antibiotic treatment of shigellosis is very important and greatly reduces the complications caused by it. Antibiotic-resistant strains such as aminoglycosides have been reported

worldwide. Studies have shown that *Shigella* strains contain aminoglycoside-modifying enzymes (AMEs) that induce resistance to aminoglycosides through three reactions: adenylation, phosphorylation, and acetylation (11). Studies have shown an increase in the prevalence of *aph*, *aacA-aphD*, and *aadE* genes among bacteria. So Vaziri *et al.* Showed that *aac* (6') -

*I*, *aac* (6') - *II*, and *ant* (2'') - *Ic* and *aph*(3')- *IV* genes in *Pseudomonas aeruginosa* cause aminoglycoside resistance in Iran, and in this study *aac*(6')- *II* gene by 36% was the most common gene and the lowest gene was *aph*(3')- *IV* (27).

In our study, the amount of *aph* gene was very low and was observed in only one strain of *Shigella dysenteriae*. Also, in 2019, Silva *et al.* showed that *Campylobacter jejuni* isolates contain *aph3-1* and *aadE* genes, which cause aminoglycoside resistance. On the other hand, *aph3-1* resistance gene was the most common gene, and *aadE* gene had the lowest abundance among *Campylobacter jejuni* isolates, and strains with *aadE* gene showed resistance to streptomycin. These results are not consistent with our study because the *aadE* gene was the most common gene (83.3%) among *Shigella dysenteriae* isolates (13). In general, it can be concluded that this gene causes streptomycin resistance in *Shigella dysenteriae* and *Campylobacter jejuni*. In 2003, Strommenger *et al.* in a study showed that the presence of *aacA-aphD1* and *aacA-aphD2* genes in *Staphylococcus aureus* makes strains resistant to gentamicin, and about half of the strains contained these genes, which was a significant amount (28). The results of this study were consistent with our research because the *aacA-aphD* gene was also seen in half of *Shigella dysenteriae* strains, so it can be concluded that the *aacA-aphD* aminoglycoside resistance gene is present in both gram-positive and gram-negative bacteria. The results of Moniri *et al.*'s research in 2010 showed that out of 60 isolates of *Acinetobacter baumannii* examined, more than 60% contain *aphA6* and *aac1* genes, which cause resistance to amikacin and tobramycin (29). The results of this study were consistent with our study because the abundance of *aacA-aphD* gene was 50%. In other words, it can be concluded that the *aac* gene in gram-negative bacteria causes resistance to aminoglycosides and that this gene should be considered. Turmeric has long been regarded for its antibacterial, therapeutic, and anti-cancer properties, and people in Asian countries have used this valuable substance to treat inflammations, gastrointestinal and respiratory diseases, and toothache. The pharmacological and antibacterial properties of turmeric are due to the presence of an important phenolic compound called curcumin. This property of curcumin is due to the presence of hydroxyl groups in the aromatic ring of phenolic compounds. At higher concentrations of phenolic compounds, due to the increase in the number of hydroxyl groups, the probability of hydrogen donation to the free radical and, following that, inhibition increases (30). Curcumin is less used in clinical cases due to its bioavailability and low absorption in the body, and

scientists have improved its effectiveness with nanotechnology (17).

Now, with the advent of aminoglycoside-resistant strains, the question is whether herbal medicines such as curcumin, despite their pharmacological and antibacterial properties, can reduce the expression of aminoglycoside resistance genes in *Shigella dysenteriae* bacteria, the cause of shigellosis. Therefore, our study is about the effect of curcumin nanoparticles on the expression of *aadE* gene, which was present in 83.3% of the isolates. So far, studies on the antibacterial effects of curcumin on bacteria have been conducted. For example, De *et al.* showed that the growth of 81% of *Helicobacter pylori* isolates was inhibited at a concentration of 10 µg/mL of curcumin (31). The MIC results of this study were inconsistent with our study, but the growth-inhibiting effect of curcumin on gastrointestinal bacteria is proven. Shariati *et al.* showed that the MIC of water-soluble curcumin nanoparticles (128 µg/mL) was less than that of nanoparticles dissolved in dimethyl sulfoxide (256 µg/mL) for *Pseudomonas aeruginosa* (32). In our study, curcumin nanoparticles were dissolved in dimethyl sulfoxide, and their MIC was almost identical to the MIC of nanoparticles dissolved in De's study. In a research conducted by Kareem *et al.* to study curcumin on *Shigella dysenteriae* and *Campylobacter jejuni* in 2020, the MIC of curcumin for *Shigella dysenteriae* was 256 µg/mL and for *Campylobacter jejuni* was 512 µg/mL (19). In our study, nanotechnology was used to improve the effectiveness of curcumin, which improved the performance of curcumin on *Shigella dysenteriae* and reduced the minimum growth inhibitory concentration compared to Kareem's research to 225 µg/mL. Therefore, the nanoization of curcumin particles is more effective than curcumin.

## 5. Conclusion

The genes studied in the research can be considered prominent in the pathogenicity of this bacterium. By comparing the results of previous studies with the present study, it is concluded that nanotechnology improves the performance of curcumin particles and creates higher sensitivity in bacterial cells because curcumin is less used due to its poor solubility in water, rapid decomposition and bioavailability. This study investigated the aminoglycoside molecular resistance genes *aadE*, *aacA-aphD*, *aph* *Shigella dysenteriae* isolated from children and their expression under the influence of curcumin nanoparticles. Based on the results of this study, curcumin nanoparticles at a concentration of 225 µg / mL inhibit the growth of *Shigella dysenteriae* bacteria. The Sub MIC concentration of curcumin nanoparticles (128 µg/mL) was used to investigate the expression of

the *aadE* gene. By comparing isolates containing *aadE* gene treated with curcumin with untreated isolates, the expression of this gene decreased, and the relative amount of Fold change was recorded in treated isolates of -1.03. In general, it can be concluded that using an appropriate dose of curcumin can effectively reduce the expression of aminoglycoside resistance genes and be used in clinical cases.

### Acknowledgment

The authors of the article express their gratitude to the staff of Pasargad Microbiology Research Laboratory (Tehran), especially Dr. Amini, and all the loved ones who had useful and valuable guidance in carrying out this scientific activity.

### Ethics Approval

This article is extracted from a master's thesis with research code 1212900690859001400162493751

### Reference

- Jomehzadeh N, Afzali M, Ahmadi K, Salmanzadeh S, Mehr F. Antimicrobial resistance patterns and prevalence of integrons in *Shigella* species isolated from children with diarrhea in southwest Iran. *Asian Pac J Trop Med*. 2021;14(2):78-82. [DOI:10.4103/1995-7645.281529]
- Amini K, Konkori M. Identification of Broad-Spectrum Beta-lactamase CTX-M-2, CTX-M-8, and Ampc-dependent CMY Genes in *Shigella sonnei* Isolated from Pediatric Diarrhea Specimens by Multiplex-PCR and Antibiotic Resistance Pattern Determination. *Iran J Med Microbiol*. 2020;14(5):501-11. [DOI:10.30699/ijmm.14.5.501]
- Zhi S, Parsons BD, Szelewicki J, Yuen YTK, Fach P, Delannoy S, et al. Identification of Shiga-Toxin-Producing *Shigella* Infections in Travel and Non-Travel Related Cases in Alberta, Canada. *Toxins* [Internet]. 2021; 13(11). [DOI:10.3390/toxins13110755] [PMID] [PMCID]
- Ranjbar R, Soltan Dallal MM, Talebi M, Pourshafie MR. Increased isolation and characterization of *Shigella sonnei* obtained from hospitalized children in Tehran, Iran. *J Health Popul Nutr*. 2008;26(4):426-30. [DOI:10.3329/jhpn.v26i4.1884] [PMID] [PMCID]
- Ke X, Gu B, Pan S, Tong M. Epidemiology and molecular mechanism of integron-mediated antibiotic resistance in *Shigella*. *Arch Microbiol*. 2011;193(11):767. [DOI:10.1007/s00203-011-0744-3] [PMID]
- Kahsay AG, Muthupandian S. A review on Sero diversity and antimicrobial resistance patterns of *Shigella* species in Africa, Asia and South America, 2001-2014. *BMC Res Notes*. 2016;9(1):422. [PMID] [DOI:10.1186/s13104-016-2236-7] [PMCID]
- Afshari N, Bakhshi B, Mahmoudi aznavah A, Fallah F, Rahbar M, Rafiei Tabatabaei S. Investigation of prevalence of *Shigella sonnei* in children with diarrhea admitted to two hospital Emam Khomeini and Milad in Tehran in 1391 with Antimicrobial susceptibility of isolates. *Iran J Med Microbiol*. 2016;10(2):16-22.
- Tran Van Nhieu G, Sansonetti PJ. Mechanism of *Shigella* entry into epithelial cells. *Curr Opin Microbiol*. 1999;2(1):51-5. [DOI:10.1016/S1369-5274(99)80009-5] [PMID]
- Nasrollahi Boroujeni F, Deldar AA. The Study of the Stable Expression of IpaB, the Virulence Factor in *Shigella Sonnei*, in Terms of Simultaneous Expression of Chaperone IpgC. *Iran J Med Microbiol*. 2018;12(4):260-8. [DOI:10.30699/ijmm.12.4.260]
- Muthurandhi Sethuvel DP, Veeraraghavan B, Vasudevan K, Devanga Ragupathi NK, Murugan D, Walia K, et al. Complete genome analysis of clinical *Shigella* strains reveals plasmid pSS1653 with resistance determinants: a triumph of hybrid approach. *Gut Pathog*. 2019;11(1):55. [DOI:10.1186/s13099-019-0334-5] [PMID] [PMCID]
- Ranjbar R, Farahani A. *Shigella*: Antibiotic Resistance Mechanisms And New Horizons For

registered in the Islamic Azad University of Arak. This article has the code of ethics with the number IR.IAU.ARAK.REC.1401.003.

### Conflict of Interest

The authors declare any conflict of interest.

### Author Contribution

All authors contributed to data collection, writing, and manuscript revision. All authors read and approved the final manuscript.

### Funding

None.

- Treatment. *Infect Drug Resist.* 2019;12:3137-67. [DOI:10.2147/IDR.S219755] [PMID] [PMCID]
12. Soleimani N. Molecular Biology of Aminoglycoside and Relationship of Aminoglycoside Modifying Enzymes with Altering Resistance. *Alborz Univ Med J.* 2017;6(4):227-40. [DOI:10.29252/aums.6.4.227]
  13. Silva PR, Palma JM, Souza NR, de Moura HM, Perecmanis S, et al. Isolation and antimicrobial resistance of *Campylobacter jejuni* and *Campylobacter coli* found in chilled chicken carcasses in the Federal District Region and surrounding areas. *Semina: Ciências Agrárias.* 2019; 40(5Supl1):2247-60. [DOI:10.5433/1679-0359.2019v40n5Supl1p2247]
  14. Garneau Tsodikova S, Labby KJ. Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives. *Med Chem Comm.* 2016;7(1):11-27. [DOI:10.1039/C5MD00344J] [PMID] [PMCID]
  15. Chopra H, Dey PS, Das D, Bhattacharya T, Shah M, Mubin S, et al. Curcumin Nanoparticles as Promising Therapeutic Agents for Drug Targets. *Molecules* [Internet]. 2021;26(16):4998. [PMID] [PMCID] [DOI:10.-3390/molecules26164998]
  16. Gopal J, Muthu M, Chun SC. One-step, ultrasonication-mobilized, solvent-free extraction /synthesis of nanocurcumin from turmeric. *RSC Adv.* 2015;5(60):48391-8. [DOI:10.1039/C5RA06002H]
  17. Rai M, Ingle AP, Pandit R, Paralikar P, Anasane N, Santos CAD. Curcumin and curcumin-loaded nanoparticles: antipathogenic and antiparasitic activities. *Expert Rev Anti Infect Ther.* 2020;18(4):367-79. [DOI:10.1080/14787210.2020.1730815] [PMID]
  18. Sharifi S, Fathi N, Memar MY, Hosseiniyan Khatibi SM, Khalilov R, Negahdari R, et al. Antimicrobial activity of curcumin nanoformulations: New trends and future perspectives. *Phytother Res.* 2020; 34(8):1926-46. [DOI:10.1002/ptr.6658] [PMID]
  19. Kareem SM, Mahmood SS, Hindi NK. Effects of Curcumin and Silymarin on the *Shigella dysenteriae* and *Campylobacter jejuni* In vitro. *J Gastrointest Cancer.* 2020;51(3):824-8. [DOI:10.1007/s12029-019-00301-1] [PMID]
  20. Werner G, Hildebrandt B, Witte W. Aminoglycoside-Streptothricin Resistance Gene Cluster aadE-sat4-aphA-3 Disseminated among Multiresistant Isolates of *Enterococcus faecium*. *Antimicrob Agents Chemother.* 2001;45(11):3267-9. [DOI:10.1128/AAC.45.11-3267-3269.2001] [PMID] [PMCID]
  21. Udou T. Dissemination of nosocomial multiple-aminoglycoside-resistant *Staphylococcus aureus* caused by horizontal transfer of the resistance determinant (aacA/aphD) and clonal spread of resistant strains. *Am J Infect Control.* 2004;32(4):215-9. [DOI:10.1016/j.ajic.2003.11.002] [PMID]
  22. Gião J, Leão C, Albuquerque T, Clemente L, Amaro A. Antimicrobial Susceptibility of *Enterococcus* Isolates from Cattle and Pigs in Portugal: Linezolid Resistance Genes *optrA* and *poxtA*. *Antibiotics* [Internet]. 2022; 11(5). [PMID] [PMCID] [DOI:10.3390/anti-biotics11050615]
  23. Bhawana, Basniwal RK, Buttar HS, Jain VK, Jain N. Curcumin Nanoparticles: Preparation, Characterization, and Antimicrobial Study. *J Agric Food Chem.* 2011;59(5):2056-61. [DOI:10.1021/jf104402t] [PMID]
  24. Alizadeh Sarvandani S, Amini K, Saffarian P. Evaluation of antimicrobial activity of Curcumin nanoparticles on the gene expression of the enterococcal surface protein, Esp, involved in biofilm formation of *Enterococcus Faecalis*. *Razi J Med Sci.* 2019;26(9):39-46.
  25. Panahi Y, Monnazah MA, Vafaei G. Study of the Use of Dimethyl Sulfoxide (DmsO) As A Solvent in the Administration of Antiepileptic Drugs. *Stud Med Sci.* 2020;31(4):316-24.
  26. Sayers EW, Barrett T, Benson DA, Bolton E, Bryant SH, et al. Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.* 2018;46(D1):D8-d13.
  27. Vaziri F, Peerayeh SN, Nejad QB, Farhadian A. The prevalence of aminoglycoside-modifying enzyme genes (aac (6')-I, aac (6')-II, ant (2'')-I, aph (3')-VI) in *Pseudomonas aeruginosa*. *Clin Sci.* 2011;66(9):1519-22.
  28. Strommenger B, Kettlitz C, Werner G, Witte W. Multiplex PCR Assay for Simultaneous Detection of Nine Clinically Relevant Antibiotic Resistance Genes in *Staphylococcus aureus*. *J Clin Microbiol.* 2003;41(9):4089-94. [DOI:10.1128/JCM.41.9.4089-4094.2003] [PMID] [PMCID]
  29. Moniri R, Farahani RK, Shajari G, Shirazi MN, Ghasemi A. Molecular epidemiology of aminoglycosides resistance in *acinetobacter* spp. With emergence of multidrug-resistant strains. *Iran J Public Health.* 2010;39(2):63-8.
  30. Zhang Z, Liao L, Moore J, Wu T, Wang Z. Antioxidant phenolic compounds from walnut kernels (*Juglans regia* L.). *Food Chem.* 2009;113(1):160-5. [DOI:10.1016/j.foodchem.2008.07.061]

31. De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, et al. Antimicrobial Activity of Curcumin against *Helicobacter pylori* Isolates from India and during Infections in Mice. *Antimicrob Agents Chemother*. 2009;53(4):1592-7. [[DOI:10.1128/AAC.01242-08](https://doi.org/10.1128/AAC.01242-08)] [[PMID](#)] [[PMCID](#)]
32. Shariati A, Asadian E, Fallah F, Azimi T, Hashemi A, Yasbolaghi Sharahi J, et al. Evaluation of Nano-curcumin effects on expression levels of virulence genes and biofilm production of multidrug-resistant *Pseudomonas aeruginosa* isolated from burn wound infection in Tehran, Iran. *Infect Drug Resist*. 2019;12:2223-35. [[DOI:10.2147/IDR.S213200](https://doi.org/10.2147/IDR.S213200)] [[PMID](#)] [[PMCID](#)]